By contrast, a 3-marker panel of plasma proteins (APOD, PSMA7 and HPT) predicted endometrial cancer with an AUC of 0.87 (0.81–0.93), sensitivity of 75% (64%–86%), and specificity of 84% (75%–93%). This evidence concerns the gene APOD and endometrial cancer.